Li Tingting, Wang Guanyu, Zhang Chunlei, Wang Wenhui, Li Chunting, Wang Yimeng
Department of Dermatology, Peking University Third Hospital, Beijing, China.
Department of Dermatology, Tianjin People's Hospital, Tianjin, China.
Front Med (Lausanne). 2025 Apr 28;12:1544912. doi: 10.3389/fmed.2025.1544912. eCollection 2025.
Cutaneous T-cell lymphoma (CTCL) often presents with early-stage clinical features indistinguishable from atopic dermatitis (AD), posing significant diagnostic challenges. Recent studies have highlighted cases where patients initially diagnosed with AD and treated with biologic agents were subsequently reclassified as having CTCL, though the nature of this relationship remains poorly understood. In this report, we present two cases of mycosis fungoides and one case of Sézary syndrome (SS), all initially diagnosed as AD and treated with biologic agents, including dupilumab. Furthermore, we conducted a literature review exploring potential associations between AD, biologic agents, and CTCL. Our objective is to improve clinicians' ability to differentiate between AD and CTCL and to provide evidence supporting a possible association between biologic treatments and CTCL. Our findings highlight the need for heightened clinical vigilance and the routine use of skin biopsy in refractory eczematous presentations.
皮肤T细胞淋巴瘤(CTCL)通常表现出与特应性皮炎(AD)难以区分的早期临床特征,这带来了重大的诊断挑战。最近的研究强调了一些病例,即最初被诊断为AD并接受生物制剂治疗的患者随后被重新分类为患有CTCL,尽管这种关系的本质仍知之甚少。在本报告中,我们展示了两例蕈样肉芽肿和一例 Sézary 综合征(SS),所有病例最初均被诊断为AD并接受了包括度普利尤单抗在内的生物制剂治疗。此外,我们进行了一项文献综述,探讨AD、生物制剂和CTCL之间的潜在关联。我们的目标是提高临床医生区分AD和CTCL的能力,并提供证据支持生物治疗与CTCL之间可能存在的关联。我们的研究结果强调了在难治性湿疹表现中提高临床警惕性和常规进行皮肤活检的必要性。